Antimicrobials

Biodefense Headlines – 31 March 2025

Biosecurity March 31, 2025

This week’s topics include restructuring of ASPR, anti-vaccine leadership at NIH, the UK’s new pathogen priority research targets list, and data on a post-exposure treatment for filoviruses. FEATURED Trump Administration…

EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

MIT Researchers Make Progress on Antibiotic Resistance Under DTRA-JSTO Research Program

Understanding How the Microbiome Affects Radiation Injury for Countermeasure Development

Is it a Bacterial or Viral Infection? Novel MeMed Rapid Test Receives FDA Clearance

New Tool in the AMR Fight: Synthetic RNA That Hugs Bad Bacterial RNA and Won’t Let Go

2021 BAA for Development of Medical Countermeasures for Biological Threats

Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States

BARDA Vaccines Against AMR Threats Virtual Workshop

New Vaccine Development Platform Could Fight Deadly, Multi-Drug Resistant Bacteria

Defense Threat Reduction Agency Awards $75M for Antibiotic Drug Development

Scientists Engineer Bacteria-Killing Molecules from Wasp Venom

Basilea Awarded Additional Funding from U.S. Medical Countermeasure Program for Ceftobiprole Development

Genome of Alexander Fleming’s Original Penicillin-Producing Mould Sequenced

NIAID to Hold Closed Meeting on Biodefense Medical Countermeasure Funding

Titanium–Gadolinium Quantum Dot Staining Agent Specific to Bacterial Cells

Trial Shows Two Drugs Not Better Than One When Treating MRSA

51 FDA Approved Medical Countermeasures Backed by BARDA

Carb-X Funds Techulon’s Rapidly Adaptable Nano Therapeutic in Fight Against Drug Resistant Bacteria

A ‘Shocking’ New Way To Treat Infections

In Fight Against Superbugs, BARDA Looks to Shore Up National Stockpile Countermeasures

Biodefense Headlines – 31 March 2025